Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion type Assertion NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_head.
- NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_provenance.
- NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion evidence source_evidence_literature NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_provenance.
- NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion SIO_000772 23989980 NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_provenance.
- NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion wasDerivedFrom befree-20150227 NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_provenance.
- NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_assertion wasGeneratedBy ECO_0000203 NP802787.RAWRXgGOGCEbGhLDigU6UIbho-d26ONlI-1uY7Ub_9QDM130_provenance.